[go: up one dir, main page]

IT1255770B - ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE - Google Patents

ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE

Info

Publication number
IT1255770B
IT1255770B ITMI921235A ITMI921235A IT1255770B IT 1255770 B IT1255770 B IT 1255770B IT MI921235 A ITMI921235 A IT MI921235A IT MI921235 A ITMI921235 A IT MI921235A IT 1255770 B IT1255770 B IT 1255770B
Authority
IT
Italy
Prior art keywords
translocation
antisense oligonucleotides
chromosome
pharmaceutical compositions
relates
Prior art date
Application number
ITMI921235A
Other languages
Italian (it)
Inventor
Susanna Morelli
Angelo Nicolin
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Priority to ITMI921235A priority Critical patent/IT1255770B/en
Publication of ITMI921235A0 publication Critical patent/ITMI921235A0/en
Priority to PCT/EP1993/001287 priority patent/WO1993024653A1/en
Publication of ITMI921235A1 publication Critical patent/ITMI921235A1/en
Application granted granted Critical
Publication of IT1255770B publication Critical patent/IT1255770B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invenzione riguarda oligonucleotidi antisenso (aODN) che comprendono sequenze di nucleotidi caratterizzati dalla possibilità di ibridizzare, anche all'interno delle cellule umane, con regioni delle molecole del codice genetico originate dalla traslocazione di un tratto di cromosoma 18 su altri cromosomi, in particolare il cromosoma 14. La traslocazione cromosomica è la causa di numerose forme patologiche, in particolare tumori. L'inibizione degli effetti biologici della traslocazione da parte di oligonucleotidi antisenso ha significato conoscitivo, diagnostico e terapeutico.L'invenzione riguarda l'uso di tali antisenso per lo studio la diagnosi e la terapia dei tumori originati dalla traslocazione cromosomica t (14;18) e le modificazioni chimiche e farmaceutiche atte a renderle idonee per la somministrazione in campo umano.The present invention relates to antisense oligonucleotides (aODN) which include nucleotide sequences characterized by the possibility of hybridizing, also within human cells, with regions of the molecules of the genetic code originating from the translocation of a tract of chromosome 18 on other chromosomes, in particular chromosome 14. Chromosome translocation is the cause of numerous pathological forms, in particular tumors. The inhibition of the biological effects of translocation by antisense oligonucleotides has cognitive, diagnostic and therapeutic significance. The invention relates to the use of these antisense for the study the diagnosis and therapy of tumors originating from chromosomal translocation t (14; 18 ) and chemical and pharmaceutical modifications to make them suitable for administration in the human field.

ITMI921235A 1992-05-22 1992-05-22 ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE IT1255770B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITMI921235A IT1255770B (en) 1992-05-22 1992-05-22 ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE
PCT/EP1993/001287 WO1993024653A1 (en) 1992-05-22 1993-05-21 Antisense oligonucleotides with antitumoral activity, pharmaceutical compositions which comprise them, and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI921235A IT1255770B (en) 1992-05-22 1992-05-22 ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE

Publications (3)

Publication Number Publication Date
ITMI921235A0 ITMI921235A0 (en) 1992-05-22
ITMI921235A1 ITMI921235A1 (en) 1993-11-22
IT1255770B true IT1255770B (en) 1995-11-15

Family

ID=11363352

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI921235A IT1255770B (en) 1992-05-22 1992-05-22 ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE

Country Status (2)

Country Link
IT (1) IT1255770B (en)
WO (1) WO1993024653A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1189573A (en) * 1994-10-14 1999-04-06 Yutaka Shindo Apoptosis-relating gene
IT1276642B1 (en) * 1995-03-03 1997-11-03 Consiglio Nazionale Ricerche ANTI-SENSE TRANSCRIPT PRESENT IN B LYMPHOCYTES AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL FOR INHIBIRING THEIR ACTION
IT1275862B1 (en) * 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT
DE19610255B4 (en) * 1996-03-15 2004-11-04 Universität Heidelberg Process for the preparation of nucleic acid sequences and process for the detection of translocations between chromosomes
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0878552A1 (en) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
JP2002513587A (en) 1998-05-04 2002-05-14 ダコ エー エス Methods and probes for detecting chromosomal abnormalities

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
JPH06501160A (en) * 1990-09-17 1994-02-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for controlling cell proliferation
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides

Also Published As

Publication number Publication date
WO1993024653A1 (en) 1993-12-09
ITMI921235A0 (en) 1992-05-22
ITMI921235A1 (en) 1993-11-22

Similar Documents

Publication Publication Date Title
Young et al. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals
TWI272273B (en) Platinum compounds
Weiss et al. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation.
Dietrich et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo
Cholody et al. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors
Takusagawa et al. The structure of a pseudo intercalated complex between actinomycin and the DNA binding sequence d (GpC)
IT1255770B (en) ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
BR0017048A (en) Phosphonate bisamidate prodrugs
BG103616A (en) Derivatives of arylsulphonylaminohydroxamic acid
HUP0100786A2 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
DE60237158D1 (en) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
TNSN99177A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDO [1, 2-a] PYRAZINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
ATE215099T1 (en) CATIONIC POLYMERS, COMPLEXES CONTAINING THESE CATIONIC POLYMERS AND THERAPEUTIC AGENTS CONTAINING AT LEAST ONE NEGATIVE CHARGE, IN PARTICULAR NUCLEIC ACIDS AND THEIR USE IN GENE THERAPY
CA2276306A1 (en) Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer
Liu et al. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells
DE602004027255D1 (en) Peptidic compounds and their derivatives for the treatment of human diseases by inhibiting the transmission of signals via growth factors
Kolarić et al. Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors
Double et al. Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterization of an ascitic line
Hausmanowa-Petrusewicz et al. Intrafamilial variability of X-linked progressive muscular dystrophy: Mild and acute form of X-linked muscular dystrophy in the same family
Lea et al. Action of Miracil D and related compounds on DNA and RNA synthesis in regenerating liver and hepatomas
Heim et al. Constitutional C-band pattern in patients with adenomatosis of the colon and rectum
Lee et al. Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers
Peter et al. Oxidative phosphorylation and calcium transport by sarcotubular vesicles in myotonic dystrophy
Britten et al. Supply and need of factor VIII concentrates

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970522